Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PMDA’s Preliminary Meetings, Face-to-Face Counseling Rise in FY2013
April 28, 2014
- Chuikyo Healthcare Provider Rep Vexed by Health Minister Proposal on Use of Drug Cost-Effective Assessment
April 25, 2014
- JMA Veep Nakagawa Fumes at Industry, Says “Application Lag” Elicited New Mixed Care Proposal
April 25, 2014
- Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
- LDP Study Group to Call for Expansion of R&D Tax Credit System, Oppose Annual NHI Price Cuts
April 24, 2014
- PAFSC’s Second Committee to Discuss Janssen, Sanofi Prostate Cancer Drugs on April 30
April 23, 2014
- Public Knowledge-Based Applications Appropriate for Propranolol, Levonorgestrel: Panel
April 23, 2014
- Health Minister Wary about Annual Drug Price Cuts, but Aso, Amari Give Backing
April 23, 2014
- Min. Tamura Positive about Mixed Care Discussions with Govt Panel
April 22, 2014
- MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
- DPJ Member Nagatsuma Asks MHLW to Consider Criminal Complaint over SIGN Trial
April 18, 2014
- New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
- Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
- Govt Deregulation Panel Tenders Prerequisites for Envisaged Mixed Care System
April 17, 2014
- MHLW to Mull Applying Mixed Care Scheme to Low Cost-Effective Drugs: Minister
April 17, 2014
- Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
- PAFSC’s First Committee to Review Canagliflozin, Japan’s 5th SGLT-2 Inhibitor
April 15, 2014
- Pharma Leaders Push Abe Govt to Permanently Introduce Key Premium, R&D Tax Credit
April 15, 2014
- MHLW Panel on Counterfeit Drugs Holds First Meeting
April 14, 2014
- MHLW Diovan Panel Finalizes Report following Fine-Tuning
April 14, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…